Jackline Joy Lasola

Jackline Joy Lasola

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2011 in Molecular Phylogenetics and Evolution
Verified
Journal Article
Closed access
POPatrick M. O’gRady
Patrick M. O’gRady
RLRichard T. Lapoint
Richard T. Lapoint
JBJames Bonacum
James Bonacum
JLJackline Joy Lasola
Jackline Joy Lasola
EOElaine Owen
Elaine Owen
RDRob DeSalle
Rob DeSalle

3 February 2016 in Journal of Viral Hepatitis
Verified
Journal Article
Closed access
PDF file
OFOluwaseun Falade-Nwulia
Oluwaseun Falade-Nwulia
SMS. H. Mehta
S. H. Mehta
JLJackline Joy Lasola
Jackline Joy Lasola
Carl LatkinCarl Latkin
Carl Latkin
ANA. Niculescu
A. Niculescu
DTD. L. Thomas
D. L. Thomas

2 November 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JLJackline Joy Lasola
Jackline Joy Lasola
ACAndrea L. Cottingham
Andrea L. Cottingham
BSBrianna L. Scotland
Brianna L. Scotland
NTNhu Truong
Nhu Truong
CHCharles Hong
Charles Hong
RPRyan Pearson
Ryan Pearson
Inflammation is a key homeostatic process involved in the body’s response to a multitude of disease states including infection, autoimmune disorders, cancer, and other chronic conditions. When the initiating event is poorly controlled, severe inflammation and globally dysregulated immune responses can occur. To address the lack of therapies that efficaciously address the multiple aspects of the dysregulated immune response, we developed cargo-less immunomodulatory nanoparticles (iNPs) comprised of poly(lactic acid) (PLA) with either poly(vinyl alcohol) (PVA) or poly(ethylene-alt-maleic acid) (PEMA) as stabilizing surfactants and investigated the mechanisms by which they exert their inherent anti-inflammatory effects. We identified that iNPs leverage a multimodal mechanism of action by physically interfering with the interactions between pathogen-associated molecular patterns (PAMPs) and bone marrow-derived macrophages (BMMΦs). Additionally, we showed that iNPs mitigate proinflammatory cytokine secretions induced by LPS via a time- and composition-dependent abrogation of NF-κB p65 and p38 MAPK activation. Lastly, inhibition studies were performed to establish the role of a pH-sensing G-protein-coupled receptor, GPR68, on contributing to the activity of iNPs. These data provide evidence for the multimodal mechanism of action of iNPs and establish their potential use as a novel therapeutic for the treatment of severe inflammation.

4 August 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
JLJackline Joy Lasola
Jackline Joy Lasola
HKHenry Kamdem
Henry Kamdem
MMMichael W. McDaniel
Michael W. McDaniel
RPRyan Pearson
Ryan Pearson
Inflammation is an essential component of a wide variety of disease processes and oftentimes can increase the deleterious effects of a disease. Finding ways to modulate this essential immune process is the basis for many therapeutics under development and is a burgeoning area of research for both basic and translational immunology. In addition to developing therapeutics for cellular and molecular targets, the use of biomaterials to modify innate and adaptive immune responses is an area that has recently sparked significant interest. In particular, immunomodulatory activity can be engineered into biomaterials to elicit heightened or dampened immune responses for use in vaccines, immune tolerance, or anti-inflammatory applications. Importantly, the inherent physicochemical properties of the biomaterials play a significant role in determining the observed effects. Properties including composition, molecular weight, size, surface charge, and others affect interactions with immune cells (i.e., nano-bio interactions) and allow for differential biological responses such as activation or inhibition of inflammatory signaling pathways, surface molecule expression, and antigen presentation to be encoded. Numerous opportunities to open new avenues of research to understand the ways in which immune cells interact with and integrate information from their environment may provide critical solutions needed to treat a variety of disorders and diseases where immune dysregulation is a key inciting event. However, to elicit predictable immune responses there is a great need for a thorough understanding of how the biomaterial properties can be tuned to harness a designed immunological outcome. This review aims to systematically describe the biological effects of nanoparticle properties—separate from additional small molecule or biologic delivery—on modulating innate immune cell responses in the context of severe inflammation and sepsis. We propose that nanoparticles represent a potential polypharmacological strategy to simultaneously modify multiple aspects of dysregulated immune responses where single target therapies have fallen short for these applications. This review intends to serve as a resource for immunology labs and other associated fields that would like to apply the growing field of rationally designed biomaterials into their work.

14 December 2017 in Cancer Research
Verified
Journal Article
Open access
PDF file
SKSabina Kaczanowska
Sabina Kaczanowska
AJAnn Mary Joseph
Ann Mary Joseph
JGJitao Guo
Jitao Guo
ATAlexander K Tsai
Alexander K Tsai
JLJackline Joy Lasola
Jackline Joy Lasola
EDEduardo Davila
Eduardo Davila
T cell–based immunotherapies are a promising approach for patients with advanced cancers. However, various obstacles limit T-cell efficacy, including suboptimal T-cell receptor (TCR) activation and an immunosuppressive tumor environment. Here, we developed a fusion protein by linking CD8α and MyD88 (CD8α:MyD88) to enhance CD8+ T-cell responses to weakly immunogenic and poorly expressed tumor antigens. CD8α:MyD88–engineered T cells exhibited increased proliferation and expression of effector and costimulatory molecules in a tumor antigen–dependent manner. These effects were accompanied by elevated activation of TCR and Toll-like receptor signaling-related proteins. CD8α:MyD88–expressing T cells improved antitumor responses in mice. Enhanced antitumor activity was associated with a unique tumor cytokine/chemokine signature, improved T-cell infiltration, reduced markers of T-cell exhaustion, elevated levels of proteins associated with antigen presentation, and fewer macrophages with an immunosuppressive phenotype in tumors. Given these observations, CD8α:MyD88 represents a unique and versatile approach to help overcome immunosuppression and enhance T-cell responses to tumor antigens. Cancer Res; 77(24); 7049–58. ©2017 AACR.

12 June 2020 in Communications Biology
Verified
Journal Article
Open access
PDF file
DGDegui Geng
Degui Geng
NCNicholas Ciavattone
Nicholas Ciavattone
JLJackline Joy Lasola
Jackline Joy Lasola
RSRojesh Shrestha
Rojesh Shrestha
ASAmelia Sanchez
Amelia Sanchez
EDEduardo Davila
Eduardo Davila
Melanoma represents the most serious type of skin cancer. Although recent years have seen advances using targeted and immunotherapies, most patients remain at high risk for tumor recurrence. Here we show that IRAK-M, a negative regulator of MyD88 signaling, is deficient or low in melanoma and expression levels correlate with patient survival. Inducing IRAK-M expression using genetic approaches or epigenetic modifiers initiates apoptosis by prompting its interaction with TRAF6 via IRAK-M’s C-terminal domain. This complex recruits and degrades calpastatin which stimulates calpain activity and triggers caspase-3-dependent but caspase-8,−9-independent apoptosis. Using a drug screen, we identified compounds that induced IRAK-M expression. Administration of IRAK-M-inducing drugs reduced tumor growth in mice but was ineffective against IRAK-M knock-down tumors. These results uncover a previously uncharacterized apoptosis pathway, emphasize IRAK-M as a potential therapeutic target and suggest that the anticancer activity of certain drugs could do so through their ability to induce IRAK-M expression.